- Home
- ONCO vs TNXP Comparison
ONCO vs TNXP Comparison
Compare ONCO & TNXP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ONCO
- TNXP
- Stock Information
- Founded
- ONCO 2018
- TNXP 2007
- Country
- ONCO United States
- TNXP United States
- Employees
- ONCO N/A
- TNXP N/A
- Industry
- ONCO Biotechnology: Pharmaceutical Preparations
- TNXP Biotechnology: Pharmaceutical Preparations
- Sector
- ONCO Health Care
- TNXP Health Care
- Exchange
- ONCO Nasdaq
- TNXP Nasdaq
- Market Cap
- ONCO 24.1M
- TNXP 19.5M
- IPO Year
- ONCO 2022
- TNXP N/A
- Fundamental
- Price
- ONCO $1.27
- TNXP $0.13
- Analyst Decision
- ONCO
- TNXP Strong Buy
- Analyst Count
- ONCO 0
- TNXP 2
- Target Price
- ONCO N/A
- TNXP $53.50
- AVG Volume (30 Days)
- ONCO 71.6K
- TNXP 13.8M
- Earning Date
- ONCO 11-26-2024
- TNXP 11-12-2024
- Dividend Yield
- ONCO N/A
- TNXP N/A
- EPS Growth
- ONCO N/A
- TNXP N/A
- EPS
- ONCO N/A
- TNXP N/A
- Revenue
- ONCO $1,463,746.00
- TNXP $11,291,000.00
- Revenue This Year
- ONCO N/A
- TNXP $62.53
- Revenue Next Year
- ONCO N/A
- TNXP $26.17
- P/E Ratio
- ONCO N/A
- TNXP N/A
- Revenue Growth
- ONCO N/A
- TNXP 183.05
- 52 Week Low
- ONCO $1.27
- TNXP $0.12
- 52 Week High
- ONCO $21.40
- TNXP $22.08
- Technical
- Relative Strength Index (RSI)
- ONCO 20.68
- TNXP 33.87
- Support Level
- ONCO $1.70
- TNXP $0.13
- Resistance Level
- ONCO $2.53
- TNXP $0.15
- Average True Range (ATR)
- ONCO 0.28
- TNXP 0.01
- MACD
- ONCO -0.14
- TNXP 0.00
- Stochastic Oscillator
- ONCO 0.00
- TNXP 4.86
About ONCO Onconetix Inc.
Onconetix Inc is a commercial-stage biotechnology company focused on the research, development, and commercialization of innovative solutions for men's health and oncology. It has a product named Entadfi an FDA-approved once-daily oral therapeutic for the treatment of benign prostatic hyperplasia, a disorder of the prostate, along with building additional assets in therapeutics, diagnostics, and clinician services for oncology.
About TNXP Tonix Pharmaceuticals Holding Corp.
Tonix Pharmaceuticals Holding Corp is a biopharmaceutical company focused on developing, licensing and commercializing therapeutics to treat and prevent human disease and alleviate suffering. Tonix's development portfolio is focused on central nervous system (CNS) disorders. The company's immunology development portfolio consists of biologics to address organ transplant rejection, autoimmunity and cancer, including TNX-1500, which is a humanized monoclonal antibody targeting CD40-ligand (CD40L or CD154) being developed for the prevention of allograft rejection and for the treatment of autoimmune diseases. Tonix also has product candidates in development in the areas of rare disease and infectious disease.